SEC Form 4 · accession 0001209191-18-011264
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas Lydon
Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2018 | M | 16,483 | $4.55 | A | 304,106 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Preferred Stock Warrant (right to buy)F1,F2 | $4.55 | Feb 15, 2018 | M | 16,483 | D | — | Nov 4, 2018 | Common Stock | 16,843 | 0 | D |
Explanation of responses
- F1Immediately prior to the closing of the Issuer's initial public offering, the warrant became exercisable for shares of common stock.
- F2This warrant is exercisable at any time.